Gilead Sciences CEO O'Day sells 15,000 shares

Both sales were made pursuant to a Rule 10b5-1 trading plan adopted February 25, 2026.

Rhea-AI Filing Summary

Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day reported selling 15,000 shares of common stock in two direct transactions on October 1, 2026: 12,000 shares at a reported $147.7190 per share and 3,000 shares at $148.6265 per share. The applicable sale-price ranges were $147.21 to $148.205 and $148.23 to $149.13, respectively.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 2 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 15,000 shs ($2.22M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	12,000	$147.719	$1.77M
Sale	Common Stock F1, F3	3,000	$148.6265	$446K

Holdings After Transaction: Common Stock — 566,683 shares (Direct)

Footnotes (3)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
2. F2. Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. F3. Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold, aggregate: 15,000 shares Shares sold, first transaction: 12,000 shares Reported price, first transaction: $147.7190 per share +4 more

7 metrics

Shares sold, aggregate 15,000 shares Two direct common-stock sale transactions on October 1, 2026

Shares sold, first transaction 12,000 shares Reported on October 1, 2026

Reported price, first transaction $147.7190 per share 12,000-share transaction on October 1, 2026

Sale-price range, first transaction $147.21 to $148.205 12,000-share transaction

Shares sold, second transaction 3,000 shares Reported on October 1, 2026

Reported price, second transaction $148.6265 per share 3,000-share transaction on October 1, 2026

Sale-price range, second transaction $148.23 to $149.13 3,000-share transaction

Key Terms

Rule 10b5-1 trading plan

1 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GILD shares did Daniel Patrick O'Day sell, and at what prices?

Daniel Patrick O'Day, Gilead Sciences, Inc.'s Chairman & CEO, reported selling 15,000 shares on October 1, 2026: 12,000 at a reported $147.7190 per share and 3,000 at $148.6265 per share. The respective sale-price ranges were $147.21 to $148.205 and $148.23 to $149.13; both sales were made under a Rule 10b5-1 plan adopted February 25, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:40 PM Accepted by SEC EDGAR 10/02/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		S(1)		12,000	D	$147.719(2)	569,683	D
Common Stock	10/01/2026		S(1)		3,000	D	$148.6265(3)	566,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

2. Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)